Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. Hewison, T. Ashagre, T. Zinaida, M. Bastard, A. Hayrapetyan, S. Khurkhumal, K. Kimenye, A. Telnov, F. Varaine, M. Bonnet (Paris, France; Nukus, Uzbekistan; Yerevan, Armenia; Soukumi, Georgia; Nairobi, Kenya; Geneva, Switzerland). A multicentric cohort analysis of culture conversion and reversion in multidrug resistant tuberculosis (MDRTB) patients. Eur Respir J 2013; 42: Suppl. 57, 192

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Comparative analysis between multidrug resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB) in HIV(+) patients Source: Annual Congress 2009 - Tuberculosis and HIV co-infection Year: 2009 The MTBDRplus 2.0 for rapid diagnosis of multidrug-resistant tuberculosis among patients with high risk of TB resistance Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014 Our experience in multi drug resistant tuberculosis (MDR TB) treatment Source: Eur Respir J 2005; 26: Suppl. 49, 652s Year: 2005 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Multidrug resistant tuberculosis (MDR – TB) treatment outcomes in Iran Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Treatment outcomes of extensively-drug resistant tuberculosis (XDR-TB) patients in 20 countries Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003 Treatment results of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Eur Respir J 2005; 26: Suppl. 49, 199s Year: 2005 Frequency of risk factors for multi-drug resistant tuberculosis among the patients enrolled at multi-drug resistant clinic in a tertiary care hospital, Pakistan Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014 Multi-drug resistant tuberculosis: a retrospective analysis of cases over 10 years in a low incidence setting Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia Source: Annual Congress 2013 –Diagnostic features of tuberculosis I Year: 2013 Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Surgical treatment of multidrug resistant pulmonary tuberculosis (MDR-TB) Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011